Two ‘Step-Changing’ Drugs For Waldenström’s Macroglobulinemia Fail To Win English Funding
Executive Summary
NICE has issued final guidance for Imbruvica and preliminary guidance for Brukinsa, saying that while clinical evidence supports using the BTK inhibitors for WM, it is not convinced that either drug will be a cost-effective use of National Health Service resources.
You may also be interested in...
English Funding Rejections Reversed For Brukinsa, Adtralza, Cibinqo & Rinvoq
Health technology assessment institute NICE now believes that BeiGene’s drug for Waldenström's macroglobulinemia and three atopic dermatitis treatments, from LEO, Pfizer and AbbVie, are cost-effective.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.